Intersect Partners: Does the Incubator Model Still Work?
Executive Summary
A decade ago, during the device industry's first financing crisis, medical device incubators played a crucial role in keeping small start-ups viable. But incubators themselves soon ran into problems, most notably in finding a sustainable financing model for themselves. California-based Intersect Partners has been one of the most successful incubators but it, too, needed to find a new model to make incubation viable.
You may also be interested in...
Corporate Biotech Incubators
Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures
ev3: The Virtues of Focus
Six years ago, ev3 was launched aiming at a broad attach on cardio- and endovascular disease. But the company found including coronary devices in its mix too difficult and too costly. Instead, the company shifted directions three years ago, with a focus on peripheral and neurovascular disease. In the process, it hopes to address what it calls "the innovation gap," the lack of devices developed specifically for the PVD and neurovascular specialists.
TranS1:Transcending the Surgeon/Rep/Relationship
TranS1 is pioneering a radical approach to both fusion and minimally-invasive spine surgery. At the same time, TranS1 is also pioneering a new business model in spine, one that rests on what the company calls "transcending the surgeon/rep relationship."